Clofarabine

Clofarabine
Clinical data
Trade names	Clolar, Evoltra
AHFS/Drugs.com	Monograph
MedlinePlus	a607012
License data	EU EMA: by INN; US DailyMed: Clofarabine;
Routes of; administration	Intravenous
ATC code	L01BB06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-(6-amino-2-chloro-purin-9-yl) -4-fluoro-2- (hydroxymethyl)oxolan-3-ol;
CAS Number	123318-82-1 ;
PubChem CID	119182;
IUPHAR/BPS	6802;
DrugBank	DB00631 ;
ChemSpider	106472 ;
UNII	762RDY0Y2H;
KEGG	D03546 ;
ChEBI	CHEBI:681569 ;
ChEMBL	ChEMBL1750 ;
CompTox Dashboard (EPA)	DTXSID5046437 ;
ECHA InfoCard	100.159.663
Chemical and physical data
Formula	C10H11ClFN5O3
Molar mass	303.68 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1nc(c2ncn(c2n1)[C@@H]3O[C@@H]([C@@H](O)[C@@H]3F)CO)N;
	InChI InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1 ; Key:WDDPHFBMKLOVOX-AYQXTPAHSA-N ;
	(verify)

Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out. Ongoing trials are assessing its efficacy for managing other cancers.

^ "Clolar- clofarabine injection". DailyMed. 31 December 2019. Retrieved 27 September 2020.
^ "Evoltra EPAR". European Medicines Agency (EMA). 6 March 2009. Retrieved 27 September 2020.

[1] "Clolar- clofarabine injection". DailyMed. 31 December 2019. Retrieved 27 September 2020.

[Evoltra_EPAR-2] "Evoltra EPAR". European Medicines Agency (EMA). 6 March 2009. Retrieved 27 September 2020.

[1]

[2]